noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Power Integrations Inc.

Statement of Changes in Beneficial Ownership (Form 4)
Power Integrations Inc.

Amendment to Statement of Changes in Beneficial Ownership (Form 4/A)
Power Integrations Inc.

Amendment to Statement of Changes in Beneficial Ownership (Form 4/A)

Healthcare

Soleno Therapeutics Inc.

04/06/2026 | Press release | Distributed by Public on 04/06/2026 15:18

SLNO Social Media Post - LinkedIn (Form SC14D9C)

SLNO Social Media Post - LinkedIn

We are pleased to announce that Soleno Therapeutics has entered into a definitive agreement to be acquired by @Neurocrine Biosciences.

This transaction reflects the strength of our science, our ability to commercialize and the depth of talent and dedication across our team. It also represents the next step in our efforts to bring VYKAT XR (diazoxide choline) extended-release tablets to more people impacted by hyperphagia with Prader-Willi syndrome (PWS).

With Neurocrine’s significant scale and resources, and its deep commercialization and development experience, the combined company will be in an even stronger position to bring VYKAT XR to more individuals living with PWS-related hyperphagia and advance our development pipeline.

You can read more about the announcement here .

Soleno Therapeutics Inc. published this content on April 06, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on April 06, 2026 at 21:18 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]